Abstract:TYK2 mediates signaling of IL-23, IL-12, and Type I IFN-driven responses that are critical in immune-mediated diseases. Herein, we report the design, synthesis, and structure–activity relationships (SARs) of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors. Among them, compound 14l exhibited acceptable TYK2 inhibition with an IC50 value of 9 nM, showed satisfactory selectivity characteristics over the other three homologous JAK kinases, and performed good functional potency in the JAK/STAT signaling pathway on lymphocyte lines and human whole blood. In liver microsomal assay studies, the clearance rate and half-life of 14l were 11.4 mL/min/g and 121.6 min, respectively. Furthermore, in a dextran sulfate sodium colitis model, 14l reduced the production of pro-inflammatory cytokines IL-6 and TNF-α and improved the inflammation symptoms of mucosal infiltration, thickening, and edema. Taken together, 14l was a selective TYK2 inhibitor and could be used to treat immune diseases deserving further investigation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01468?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01468</a>.11e_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_001.pdb">PDB</a>)11e_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_002.pdb">PDB</a>)14l_in_2XA4_JAK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_003.pdb">PDB</a>)14l_in_4GJ3_TYK2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_004.pdb">PDB</a>)jmcmar_ccc (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_005.xls">XLS</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_006.csv">CSV</a>)Compounds 12a–12g with different hinge binders and their enzymatic potencies (Table S1); enzymatic potencies and the metabolic stability of compounds 13a–13l (Table S2); enzymatic potencies and the metabolic stability of compounds 14a–14o (Table S3); kinome-wide selectivity profiling of compound 14l @ 0.1 μM (Table S4); 1H NMR, 13C NMR, and HRMS-ESI of 14l, respectively (Figures S1–S3); purity of 14l (Figure S4); and biological assay methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01468/suppl_file/jm0c01468_si_007.pdf">PDF</a>)This article has not yet been cited by other publications.

Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening.

Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy

Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors

Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases

Design, Synthesis, and Biological Evaluation of Novel Phenol Ether Derivatives As Non-Covalent Proteasome Inhibitors.

Design and Biological Evaluation of Novel Imidazolyl Flavonoids As Potent and Selective Protein Tyrosine Phosphatase Inhibitors.

Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction

Substrate selection influences molecular recognition in a screen for lymphoid tyrosine phosphatase inhibitors

Design, Synthesis and Biological Activity of 4-(4-benzyloxy)phenoxypiperidines As Selective and Reversible LSD1 Inhibitors.

Design, synthesis and preliminary bioactivity studies of imidazolidine-2,4-dione derivatives as Bcl-2 inhibitors.

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors

Design, synthesis, biological evaluation, common feature pharmacophore model and molecular dynamics simulation studies of ethyl 4-(phenoxymethyl)-2-phenylthiazole-5-carboxylate as Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Discovery of 3-(4-(2-((1 H -Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1 H -pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease

Identification of 1,3,4-Thiadiazolyl-Containing Thiazolidine-2,4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity

Design, synthesis, biological evaluation and molecular modeling of novel 1,3,4-oxadiazole derivatives based on Vanillic acid as potential immunosuppressive agents.

Identification of Novel Imidazole Flavonoids As Potent and Selective Inhibitors of Protein Tyrosine Phosphatase

Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma